Qube Research & Technologies LTD Madrigal Pharmaceuticals, Inc. Transaction History

Qube Research & Technologies LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$171.37 - $283.23 $192,791 - $318,633	1,125 Added 3409.09%	1,158 $309,000
Q4 2023 Feb 13, 2024	BUY	$120.4 - $237.13 $3,973 - $7,825	33 New	33 $7,000
Q2 2022 Aug 15, 2022	BUY	$58.04 - $100.2 $599,379 - $1.03 Million	10,327 New	10,327 $739,000
Q3 2021 Nov 12, 2021	SELL	$78.35 - $105.02 $498,619 - $668,347	-6,364 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$97.2 - $137.59 $240,375 - $340,260	2,473 Added 63.56%	6,364 $620,000
Q1 2021 May 14, 2021	BUY	$108.54 - $125.2 $422,329 - $487,153	3,891 New	3,891 $455,000
Q4 2020 Feb 16, 2021	SELL	$110.06 - $133.7 $780,655 - $948,334	-7,093 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$99.78 - $124.21 $523,146 - $651,233	5,243 Added 283.41%	7,093 $842,000
Q2 2020 Aug 14, 2020	BUY	$60.13 - $125.71 $111,240 - $232,563	1,850 New	1,850 $210,000

296

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.94B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.